Yonsei University
HYE RYUN, KIM M.D., PhD
Professor, Division of Medical Oncology, Yonsei Cancer Center
EDUCATION
MD YONSEI UNIVERSITY, COLLEGE OF MEDICINE (2005)
M.S YONSEI UNIVERSITY, COLLEGE OF MEDICINE (2010)
PhD YONSEI UNIVERSITY, COLLEGE OF MEDICINE (2015)
CAREERS
RESIDENT IN INTERNAL MEDICINE, SEVERANCE HOSPITAL (2006-2010)
CLINICAL FELLOWSHIP, DIVISION OF MEDICAL ONCOLOGY, YONSEI CANCER CENTER (2010-2012)
CLINICAL ASSISTANT PROFESSOR, DIVISION OF MEDICAL ONCOLOGY, YONSEI CANCER CENTER (2012-2015)
ASSISTANT PROFESSOR, DIVISION OF MEDICAL ONCOLOGY, YONSEI CANCER CENTER (2016-2019)
ASSOCIATE PROFESSOR, DIVISION OF MEDICAL ONCOLOGY, YONSEI CANCER CENTER (2019-2024)
PROFESSOR, DIVISION OF MEDICAL ONCOLOGY, YONSEI CANCER CENTER (2024-)
AWARDS
Boryung Academic Award
Jan, 2012
APJCO Academic Award
May, 2012
Best professor award: Clinic field in Severance Hospital
2016
Best professor award: Clinic field in Severance Hospital
2017
Professor of a year 2018 in Internal Medicine College of medicine of Yonsei University
2018
Professor of a year 2019 in Internal Medicine College of medicine of Yonsei University
2019
Award of Severance Young Scientist
2020
Guangdong Medical Award
2021
Wonyoung Lee Professor of the Year in Internal Medicine
2022
Awarded the Internal Medicine Professor of the Year by the Yonsei University College of Medicine
2025
MEMBERSHIP
2012- American Society for Clinical Oncology
2010- Korean Cancer Study Group (KCSG)
2010- Korean Association for Clinical Oncology
2013- Korean Association for the Study of Lung Cancer
2013- The Korean Society for Head & Neck Oncology
2013- Active member of Lung Cancer and Head & Neck Cancer Committee of KCSG
2017- Active member of World Lung Cancer Conference
2017- Active member of American Association for Cancer Research
2024-Director of Insurance Affairs, Korean Association for the Study of Lung Cancer
2024-Deputy Secretary General, Korean Association for the Study of Lung Cancer
2024-Member, Scientific Committee, Korean Association for Clinical Oncology
2024-Secretary, Korean Association for Clinical Oncology
2024-Director of Training, Korean Society for Head & Neck Oncology
2024-Chair, KOSMOS MTB Committee, Korean Association for Clinical Oncology
2024-Board Member, Korean Cancer Association
Our Story
To enhance survival outcomes in cancer patients, we are conducting clinical trials on various novel therapeutics, including immunotherapies and targeted therapies, while simultaneously pursuing translational research to identify biomarkers, elucidate drug mechanisms of action, and investigate resistance mechanisms. In particular, we aim to develop effective therapeutic strategies to enhance anti-cancer efficacy by conducting comprehensive single-cell level analyses of immune cell interactions within the tumor microenvironment and their dynamic changes following treatment. To achieve this, we leverage patient-derived tissues and blood samples obtained from clinical trials, as well as patient-derived organoids and mouse in vivo models, ensuring our research remains closely aligned with clinical practice. Ultimately, our goal is to overcome resistance mechanisms and improve survival outcomes for cancer patients.
암 환자의 생존율 향상을 위해, 우리는 면역치료제와 표적치료제를 포함한 다양한 혁신적 치료법에 대한 임상시험을 진행하는 동시에, 바이오마커를 발굴하고, 약물 작용 기전을 규명하며, 내성 기전을 조사하기 위한 중개 연구를 수행하고 있습니다. 특히, 종양 미세환경에서 면역 세포 간 상호작용과 치료 후 나타나는 동적 변화를 단일세포 수준에서 종합적으로 분석함으로써, 항암 효능을 증진시키는 효과적인 치료 전략을 개발하는 것을 목표로 하고 있습니다. 이를 위해 임상시험에서 얻어진 환자 유래 조직과 혈액 샘플뿐 아니라 환자 유래 오가노이드 및 생체 내 마우스 모델을 활용하여 연구와 임상간의 연계를 강화하고 있습니다. 우리는 궁극적으로 항암 치료 내성을 극복하여, 생존율을 향상시키는 것을 목표로 하고 있습니다.
Contact
Always looking for new and exciting opportunities. Let's connect.